Q2 2023 Integra LifeSciences Holdings Corporation Earnings Call
Good day, and thank you for standing by.
Welcome to the Integra Lifesciences second order 2023 financial results and now like to turn the call over to Chris What senior director of Investor Relations. Please go ahead.
Thank goodness.
Good morning, and thank you for joining the Integra Lifesciences second quarter of 2023 earnings Conference call.
What are you going to call. This morning already gone to wait President and Chief Executive Officer.
Chief Financial Officer, and Matthew also buy or Vice President of corporate SG&A Investor Relations.
Yesterday evening will be issued a press release announcing our second quarter of 2023 financial results.
[noise] and corresponding earnings presentation, which will a reference during the call are available at life Dot com under investors events and presentations and a filename second quarter of 2023 earnings call presentation.
Before we begin I would like to remind you that many of the statements made during this call may be considered forward looking statements.
Factors that could cause actual results to differ materially are disclosed in the company's exchange exports filed with the SEC and and their beliefs.
Also in our prepared remarks, your reference bullets reported in organic revenue.
Organic revenue growth excludes the effects of foreign currency acquisition divestitures as well as discontinued products.
Otherwise stated all disaggregated enfranchised level revenue growth rates are based on organic performance.
Lastly, our comments today, well to a certain non-GAAP financial measures.
Reconciliations of any non-GAAP financial measures can be found in today's press release, which was an exhibit <unk>.
8-K.
Yesterday, but the S. A C.
I will now turn the call over to Yuck.
Thank you Chris.
<unk>.
What are the last to recall Photoshop.
<unk>.
Committed to sharing the timeline for streaming production in Boston during this earnings call.
I appreciate that this is top of mind for our investors and analysts sometimes for me.
So I would like to address this first before going into the planet fitness alright.
So let's start to slide four.
There's plenty of your underwear and a shake it off the consultation but yesterday.
Hold on to every global recall all politics Benefactrix.
Based on our identification of gaps in our testing process, which may have resulted in the release of products with higher levels of and adoption and permitted by the product specifications.
Recall included upfront matrix circumvents revise and tissue match punished.
We also extended the previously implemented manufacturing costs and Boston to implement additional protection and quality controls.
To be necessary in light of both recent at the inspection results and findings from prior internal and external audits.
It's important to point out that we have no specific indications of any complaints related to high end of talk some levels.
Patient safety is non-negotiable for us and we apply an abundance of caution and making tough decisions like the once we have made your own past few months.
We continue to work closely with the F D a.
We submitted an initial response to the <unk>.
Boston inspection.
A component in Maine.
And we have marched just new actions existing work plan into a comprehensive plan that we believe fully and effectively address this quality system taps.
Boston operations.
Also.
<unk>, Yeah, I'm just trying to tell me she had been project management capabilities Boston operations.
Vestments and additional internal resources and outside subject matter experts.
Spot Argumentation plan. We are also bringing in a third party audit turkogle attached to our progress if key milestones.
The cost of the project.
Based on this project plan.
To resume manufacturing by the end of this year.
I'll sit ring cycle time for moving from raw materials to finished coats in the factory.
The needs to built in century.
To complete a final <unk> outside experts.
To initiate a commercial relaunch admits too late second corner 2024.
This planet is consistent with what to expect.
With a warning letter you received last week.
We plan to continue working closely but yesterday and provide them with regular updates on our progress.
You will also submit to the F D. A to final audit report from our outside experts.
Or before March 31st 2024.
Morning lessons requires.
Turning to the right side of the slides.
It impacts on our financial results for the second quarter was significant but the line, which he estimates would be provided in a revised guidance to me.
Second quarter it'd be so negative impact of approximately $23 million from lost revenues and returns and.
The negative impact too it just E. P. S of roughly 20 cents associated with the recall.
And may.
We provided a range of impacts for 2023 and updated guidance you will see that.
Negative impact on approximately $60 million in revenues and 35 cents for a just a G. P S.
Although we are not providing guidance for 2024 at this time.
In fact, when they start time and the time required to wrap up your inventory and sales.
Create a husband for 2024.
Estimated impact of the Boston returned to market timing and <unk> <unk>.
So negatively impact the 2024 protections.
<unk> and the long range plan, which we presented during may 4th.
<unk>.
<unk> estimates this negative impact to be around $50 million and rescue and around starches sense.
P B S.
I want to show our customers and investors that are highly focused on argumentation efforts and be fully expect to complete a mediation.
<unk> is critical technologies to the markets for our customers and their patients.
So with that backdrop, let's now turn to slide five to review our second fought for business highlights.
Ah seconds called revenue decreased by 2.7%.
Organic basis, mainly reflecting the impact on the bus somebody call and production house.
However, second cause we're also reflects the strength of our markets and strong demand for our technology across the diverse portfolio of.
What do you think products and brands.
Which is you can see on the right hand side of the page resulted in total revenue above the high end of the revised guidance.
Provided to me.
Excluding products manufactured in Boston.
Portfolio landed a solid organic growth of 5.5%.
And our CSS business Crawford threatened by key projects like KUSA may fields, Georgia, and searches plus programmable files.
Back to shield creditors and instruments.
Which delivered double digit growth in the corner.
Especially with technology business, <unk> drove and key products.
Lines like back from matrix <unk>.
Those projects and many honey.
We also enjoyed strong international <unk>.
Seven per cent like by a double <unk> for CSS in China.
And high single digit girl.
I've turned into our bottom line.
Second quarter earnings per share came in at 71 cents.
Trying to sense have twins from the Boston call <unk>, otherwise strong profitability.
While the rest of our portfolio trough adjusted EPS above the high end Harvey Fist strange.
It's really beyond our second call to rescue results and back to the left side of the page.
The Olympics several positive proof points, along our path to the girls commitments laid out.
Interesting.
Continue to a toss up a portfolio strategy in the implant based breast reconstruction markets and we're excited to announce that we have files.
<unk> to the clinical section of R. P. A make application for search events.
Integration of Harvey <unk> physician as well on track and our team completed enrollment for the journal sharp PMA clinical trial.
It's clinical development spring is a step closer to having the first and second PMA products and is clinically importance and hydrograph markets.
Moving to send a link.
Made significant progress toward bringing selling back to mark.
Police at the technical fix enough finalizing testing and prepare enough funding.
Which we didn't tends to make by the end of August .
We expect to rely on the satellite monitors late in the third quarter of this year in international markets and length of the fourth quarter and the U S.
Romantic side that about settling different shades of technology, and ICP monitoring and an important catalysts to our long term commitments.
We also have expanded international reach our <unk> portfolios and we all start the clinical evidence for <unk> and the European market.
Illustrating out opportunities to bring all do you think technology is a branch to do into.
National months.
Also in the second quarter, we open our new innovation and learning Center and planes order New Jersey.
<unk>, let's talk to Richard Caruso.
Highlighting on investments in research development, and clinical education and regenerate if technologies.
And last but certainly not least reportedly at night as in <unk> at the end of June .
Yeah, I will take us through further details on the financials are updated guidance and the plan sure approaches.
Before going down and I just moved to slide six two officially introduce Leah and welcome her too and paper.
Yeah. It comes to us with more than 30 years experience in global companies, but significant operating scale and complexity.
I bought some bring it that right makes.
Makes of operational depth and strategic breath.
That'd be worth aiming for during the search via also has a great reputation for leading a developing high performing teams track records of the living strong business outcomes across the organization supports.
Five to heavily on board I look forward to her leadership it comes with <unk> twin papers future.
Before I turn to call off to Leah.
I'd like to take this time technology to contributions.
Leadership of the finest team, let bunch at most broke and Matthew Balsam iron.
<unk> have been great partners to me and I'll leadership team over the past months.
Australians Brazilians diligence and financial rigour during the C F O transition point.
With that I would like to turn to call off total yet.
Good morning, and thank you for that warm welcome.
Excited to be part of the integrity and back in the life Sciences industry.
The past three weeks I have taken the opportunity to immerse myself in getting to know our markets our products and our people.
<unk> considerable time learning about in assessing our Boston remediation plan and timeline.
There is much more to learn I'm excited about how we are positioned across potential any opportunity to leverage my experiences to help integra and its purpose to restore patient lives.
Onto our second quarter financial results and I'll start on site.
As John mentioned about the recall weighed heavily on our second quarter results.
You will see the boxer recalled impacted not only our revenues and organic growth.
Also drove to clients and our gross margins adjusted EBITDA margin and it took the a P S.
Excluding the impact from Boston.
Our second quarter results like solid growth across our diversified portfolio and provide many positive points demonstrating the strength of the underlying business that I bought highlight on the coming sites.
Can you turn to five eight I will go deeper into the second word second quite a performance of our C. F. R.
Reported second quarter revenues and C. S S $271 million, an increase of 5.1 per cent on a private basis at 6.3 per cent on inorganic basis from the prior year.
But for all the segment delivered quarterly results exceeding the growth range outlined during our investor Die.
Neurosurgery sales were up 4.2 per cent driven by the high single digit growth and advanced energy cause the capital and disposable.
Single digit growth and cerebral spinal fluid management, driven by service cost programmable mouth and back to seal.
Single digit growth enter all access to repair driven by turgeon and May field.
Single digit decline and Nora monitoring due to the prior year Com Carolyn.
Overall, excluding Sarah link capital sales.
Strong and grow double digits turn by KUSA, an atheist capital.
We remain encouraged by the continued momentum and demand financing for our capital equipment whichever resulted in double digit growth capital to the first half of this year.
Instruments grow approximately 13 per cent benefiting from continued strong demand and favorable order tiny.
The performance of our instruments and this continues to exceed longterm growth expectations like near double digit growth through the first half of this year.
Shifting to international sales grew high single digits in the order that by double digit growth in China, Canada, and our indirect market.
Consistent with our Investor day expectations, the result in China or deliberate through strong performance.
Europe .
And regional expansion.
Moving toward tissue technologies pregnant.
Nine.
Did you technologies was down 21, two per cent on a recorded basis and down 19.7 per cent on an organic basis compared to the prior year.
Excluding the Boston products reported and organic growth was 0.8% and 3.8% respectively.
Second quarter sales and one reconstruction decreased by 12% due to the bus a recall.
Despite the recall, we saw strong demand in commercial execution and double digit growth from micro matrix Psycho better honey and our nerve franchise.
We are pleased to see continued strong double digit growth through the first half from the <unk> portfolio, including micro matrix Vitale and 10 tracks.
He grows contributors and our long range plan.
And our private label franchise sales declined 43% versus last year teacher, the lost sales and returns from private label partners associated for three calls.
For clarity approximately half of the returned products on the recall or from private label partners.
And finally international thousand tissue technologies for down double digits do tend to recall in particular returns from distributor partners, which I'll set double digit growth Tetris.
[laughter].
Turning to find 10, I will now review, our second quarter peeing out matrix.
As we have discussed our second quarter revenue is down 4.2% on a recorded basis at 2.7 per cent on any panic basis, driven by the bus and recall, partially offset by solid growth across the remainder of the portfolio.
As we look broadly at our cross gross margins and profitability metrics, we are seeing improvement in our underlying gross margins offset by the impact of the Boston <unk>.
Boston headwinds gross margins for the quarter was approximately 100 basis points, which overshadow approximately 60 basis points of improvement coming from price.
<unk> volume and efficiency gains.
In addition to the anti progress margins are adjusted EBITDA Martin and it just the a P. S. Also reflect the plan and the strategic priorities that we originally outlined in January .
You want the <unk> from the sea acquisition.
These investments are critical to our long term growth. So we are protecting them to spank her <unk>.
He turned to slide 11, I will provide a brief update on our balance sheet capital structure and cashflow.
During the quarter operating cash flow was $28 million in free cash flow with $13 million recycling increased inventories as libra punish.
Punish our safety stock levels.
Free cash flow conversion was 57% I trailing 12 month basis.
Our balance sheet remains strong, but ample liquidity to support our short and long term plans.
Is it June 30th that that was $1.1 billion in Arkansas dated total leverage ratio was 2.6 times.
The company had total liquidity up $1.6 billion, including $309 million in cash and the remainder available under a revolving credit facility.
Given our favorable liquidity position confidence in our Boston restart plan and continued commitment to our short and long term growth objectives, we plan to initiate a share repurchase of $125 million by the end of the third quarter of 2023.
The share buyback is expected to contribute to 2023 and 2024 E. P. S by approximately two cents and six cents, respectively. And is included in our 2023 full year guidance as well as our 2024 fully your Boston impact.
If you turn to slide 12th I'll provide an update on our consolidated revenue and adjusted earnings per share guidance for the third quarter and full year 2023.
Third quarter revenues are forecast to be between $386 million to $390 million representing reported growth in organic growth in a range of approximately 0.2% to 1.3 per cent.
Excluding the Boston products, we are forecasting organic growth of approximately 6.7% at the midpoint driven by continued strong global demand for our products and modest improvement.
For the full year 2023 revenues are forecast to be in a range of $1.548 billion to $1.56 billion, representing reported growth minus 0.6%.
<unk> two per cent and organic growth in a range of approximately 0.3% to 1.1%.
Excluding Boston, we are forecasting organic growth of approximately 6%.
Reflecting the struggle will put the man in performance has been demonstrated in the first half.
Updated timing for the relaunch of feral link and modest supply and backward or improvements.
I'd like to highlight it went excluding the impact from the Boston recall, our full year revenue guidance remains consistent.
With our original guidance in February .
We also tightened the bottom end of our guidance ranges to reflect our queue to performance.
Turning to adjusted earnings guidance for the third quarter.
We expect adjusted E. P S to be in the range of 76 to 80 cents.
Sequentially, but down from the prior year, driven by the boss or <unk>.
Our plans procedure investment and savings to offset the impact that recall.
In April we estimate approximately 100 basis point improvement and gross margin for the full year and now with a full your impact the bus I recall, we expect only a modest improvement and gross margins versus 2022.
Our full year adjusting EPS guidance is being revised 20 range of $3.10 to $3.18 per share, which reflects our Boston revise revenue and adjusted gross margin outlook, our second half expense management as well as the announced sure be purchase.
Now I will turn the call back over to ask.
Thank you we.
They start to slide 13th.
To conclude our prepared remarks.
Despite the fact that the possibly call is required enormous focus and effort and it's overshadowing our second quarter results.
Second quarter actually provided many strong positive proof points on our business performance and both CSS did.
Digital technologies.
The underlying trend center markets are healthy procedure volumes largely back to normal.
Continuing to build resilience operational send supply chain and the performance of our portfolio. Several drivers provides confidence that we will deliver the long range girls maintenance as we move past the cute impact of the Boston recall.
Our teams are intensely focused on completing the reputation and bringing the bulk of facility to world class manufacturing and quality standards.
Whole supports the growth expectations for the products manufactured there.
And may Hilton invested they showcasing a long range targets and a half to get there.
Continue to drive progress on a long term growth initiatives.
She got her PMA portfolio strategy and implementation rescue construction.
Filing the searching for the <unk> Amendment and completed the clinical enrollment and the <unk>.
Settling is on a path to start it's returned to market by end of the third quarter and we take its place as a leading innovation.
ICP monitoring segment.
I'll start expanding our global before you buy lunch and key products from <unk> platforms and additional international markets.
Furthering our commitment to international expansion.
And with the 125 million dollar share repurchase plan, which we are launching in the third quarter.
Returning value to our shareholders.
They should.
Continue to focus on and to invest in strengthening integrous commercial and operational capabilities to drive and captured healthy organic growth opportunities in a box.
Committed to ensuring a resilience and quality manufacturing facilities.
For the past 18 months, we completed the full compliance assessment of high quality systems, and a 14 manufacturing facilities using a combination of internal and external auditors.
Making the necessary investments and processes people and equipment.
Confident that as we bring the Boston operation on quality system up to expectations.
You'll have to call the manufacturing footprint with the capabilities to drive liability quality and efficiency and.
In support of R. L. R P commitments for growth and largely accretion.
We're also investing in strategic marketing product management, and clinical evidence generation to support stronger and two n's innovation and commercial success for new product productions.
And we continue to develop our international capabilities to fully leverage market penetration and girl fact celebration opportunities in several key regions.
Outside the U S.
All of these measures will allow us to continue bringing innovative and life saving technologies to market, enabling circles searches worldwide.
Restore patient lives.
Full year outlook remains balanced.
Flexing, our commercial progress in improving execution Dawson.
It also reflects a full year impact of the Boston recall.
I'm confident that excited about the trajectory we have a dedicated team and we're focused on driving the improvements needed to unlock the full potential of this.
Business.
Thank you for joining us. This morning. This concludes our prepared remarks and or prefer we can't open the lines for questions.
Thank you if you would like to ask a question. Please press star one one on your telephone you within here an automated message advising your hands right. If you would like to remove yourself from the queue. Please press star one one again, one moment, while we prepare Q&A roster.
The first question that we have today is coming from Stephen the screen open up your ears.
Open.
Thank you good morning, guys God I was I was wondering if you can talk to the.
The two parallel things you have going on with with Ah Boston with surge of men. So you mentioned you filed for I B B R. And then you gave the updated timelines in terms of restart how are you anticipating that the timing of restart impacting the the decision process the inspection process.
For the I B B R indications, specifically and what's your latest timing in terms of when you think I b B R could potentially be on market.
Okay. So.
So as you state that there's two parts just a clinical park manufacturing parks on the clinical part.
Submit it earlier this week that tend to them that we have been talking about for a while.
And hope to have sign up from the F. D. A on that clinical piece of <unk> by the end of the year early next year.
But then there's the manufacturing.
Just equally critical to cats <unk> certification.
That part will now shift out as it all these thoughts when do we are shipping again.
At that point, we can start to do the and two n's manufacturing and product validation.
That is required to.
Have the F D a come in and do the pre approval inspection and so with the timelines that to be communicated to receive his pre approval inspection now taking place either.
424.
Early and 25, and so with that because the two are needed in parallel we see our overall PMA proof whole shifting towards the first half.
25.
With the timing was still belief.
That'll be early versus any competition.
Okay understood and.
And then just my second question is on gross margin. It. It did look certainly better than expected can.
Can you talk to some of the underlying drivers there and the sustainability.
Of those.
Even excluding even excluding Boston banks.
Okay. Thank you Steven I'm Gonna move the question to Julia Yes. Thank you good morning.
So a couple of things so first with respect to kind of how we landed versus maybe but but originally expected couple of drivers I would call out first our revenue performance in the corner was better than anticipated, which adds to make fun that drove an improvement in Martin.
Did also see an experienced more favorable manufacturing variances in the border in less than we had originally anticipated and then there was an element of we had anticipated up late happening and Q2 from a cost perspective around the remediation and some of that was temperate based on our need to address some of the <unk>.
<unk> coming from the F. D. A so all of that kind of factored into why our margins in a part of her better than we originally implied is part of our 8-K discussion.
As far I think your second question was what do we think the outlook is for the balance of the year and consistent.
Remarks that I shared earlier at this point, we are anticipating Martin's that are modestly approach versus where we landed 2022.
Great. Thanks, so much.
Thank you for your questions and one moment, while we prepare for the next question.
Our next question is coming from robbing market update.
J P. Morgan your line is open.
Hi, This is ROE in on for Robbie Thanks for taking my question.
You discussing cost savings in the second half of the year, helping to offset some of the deletion.
I'm from the lost sales.
Just want to get a sense for what you're pulling back on an S. TNA, specifically here and and what projects are <unk>.
And do you need to make up for a potentially next year. So I guess another way of asking that was is like what do you need to increase spend above trend in 2024.
So let me let me.
Of course I'm sorry.
Let me clarify the question so in our remarks, only Sharon as we remain committed to somebody plans strategic investments that we outlined as part of our discussions earlier. This year. So that's gonna continue to happen in the back half.
I I guess, it's more so like.
Are you cutting expenses and SG&A at all.
<unk> some of the lost sales and kind of improved leveraged slightly or.
Is that.
Yeah, I'm, sorry that was part of it.
Yeah, that's part of the discussion that we had when we had a.
K earlier, we talked about we're initiating some cost improvement activities in the back half to mitigate some of the impact of the recall that's still planned but we are preserving somebody has to make investments that we feel are necessary for longterm Crook Grove.
Okay, Great and then I just had another question on kind of the.
Sure loss as a result of the Boston recall.
Could you just elaborate more on when what gives you confidence that you will be able to regain the loss sure. Once you start selling these products again given it is I mean this is expected to start in the second quarter of next year and if.
If you can quantify how much sure you expect to lose if at all and and what you're using as a precedent for that.
So let me let me take a question.
Two two elements there one okay. There's a lot of focus now.
Working substitution opportunities.
For circumvents and.
Prime matrix, we have other portfolios.
We have other products with a portfolio and which we are <unk> to try to retain.
Our customers and retained relationship with customers.
At this point in time.
We assuming that tend to 50 per cent of the volume can be covered we're still learning, we're still learning and trying to increase that percentage.
And then the second part.
Part of the question how quick can we get back to you.
100 per cent sure based on.
Some experience over the past decade with other out of market situations.
Our sales leadership things that.
The year, they can get back to the market share.
Where we started and then further build up as with both surge events and.
Matrix it wasn't just about holding market share, but gaming chair tomorrow.
Mark So that that's based on experience in the past justified by both the strengths of our product quality.
Capabilities as well as the quality for commercials.
Great. Thank you.
Thank you and one moment, while we get ready for the next question.
And our next question will be coming from Matt Taylor, Oh Jaffray's. Your line is open.
Alright, great. Thanks, guys. This is the only and for Matt.
I guess, maybe the the star you know obviously, the the Boston wreath or is a really top of mind for Investor I. Appreciate all the updates there.
I I guess wanted to hear a little bit more about the various scenarios that you know you might have considered.
And you know and that got you to do the four Q restart you know, obviously I understand and there's no product issues with the F. D. A to focus on quality testing validation processes, but maybe if you can share a little bit about the you know the potential for.
Things move a little bit faster or slower as it relates to Boston.
Boston.
Yep. Thank you for that question.
Timeline.
That were communication is.
Translation of a lot of work that was done and May and most of June at where.
One hand.
We had the observations.
From the F D a in the form for eighty-three, which they communicated.
The second half of me.
And we marched dose yeah, which the <unk>. The work plan that we already had in place based on earlier external or internal observations. So that make you a very holistic plan.
Because many of the observations that we had already done internally we're not translated.
And a F D a observation.
The timeline to execute them became longer and heavier Ah given that we have to follow the copper process.
To remedy those observations, which significant bulwark root cause analysis and validation and verification. So that's one element in the plan so seconds element that we worked into the plan.
They should know.
And process external audits at a final.
Those.
Those are.
Make the corrections, where we find them in Denver, who fought.
Okay, maybe some opportunity to do some of that in <unk>.
Continuing to work, but today, we expect those findings to add to the tiny.
And then the third elements.
Which is also worked into the timing and somewhat different than what we assumed in mid may.
As we were defining the scope of the recall and the translation of the.
Regulation. We also came to the conclusion that we had to scrap the work in progress.
Half finished products in the factory.
Which adds significantly to the start of lengths.
From the moment, we start up to the moment when we have finished product. So they're all these elements added up to a restart.
The factory before and.
And of the year.
Of course, as we go along it will be discovering opportunities to either.
Cool somebody that timing in but at this point in time, we should also consider that there may be moments, where there's new words that we discover or work that we need to redo if a validation does not lead to.
The.
Uhm required outcomes. So I would say that the plan that we communicate and has some contingency in it but also I would say some risk that some new things maybe discovered then.
We're trying to discover this as early as we can forgive ourselves enough time to adjust.
Alright, great. It's a really helpful color I guess I follow up to M&A.
Strategic pillar for Integra.
How should we think about your interest or ability to do deals while working on the Boston remediation will you be approaching the M&A any differently through the next year.
Yeah, Let's let me also that would say somewhat.
I'll tell you how we are thinking about to emanate S. As you've heard us talk about are getting bored or gameboard is there with.
Yup strategic opportunities.
But there's two types of deals uhm, let gameboard, there's deals where.
<unk> pretty much controlled the timing.
Yeah, we definitely are taking a push out mindset, specifically in tissue technologies given that.
From an organization that leadership.
Definitely fully engaged on the <unk> execution.
But also there are some deals on there which are strategic supports it then where we may not controlled the timing and when those opportunities will come on the radar screen Yep, we will evaluate them.
With all the realities of the strategic importance in the short term.
<unk> realities.
And I would just filled aren't that you know our balance sheet remains strong L, where it's available or put any to execute any of that we do find a strategic opportunities that allow us to live at 10.
Kind of our long term commitment.
Alright, great. Thank you so much.
Just.
Thank you for your question one moment to the next question.
And our next question will be 10 minutes I'm, David carefully J M. T Securities. Your line is open.
Great Good morning.
I know you mentioned the.
Yeah, it's gonna come in for a <unk> preapproved and I'm just curious.
For you to start manufacturing and commercialization out of that plan.
Are you assuming right now that you will have another <unk>.
Things are either of those to happen.
So so let me clarify thank your your mixing someone to PMA discussion with you restart discussion.
F D. A has called firms that restarting manufacturing.
<unk> at our own decisions.
So we decided when would restart.
And we will then.
Also pull in an external audits and based on our decision what T. R. Oh, that's a consultant.
If that is successful it will restart.
<unk>, Okay. So there's no audits.
F D eight audit involved in restarting.
Fracturing restarting.
Restarting the shipping.
And I was talking about the pre approval inspection that is specifically.
Part of the P M a.
Uhm trajectory manufacturing <unk> trajectory.
And there.
Four see that yeah with the shipping planning that we will do that.
Pre approval inspection audit odd U F. C. That's one will take place at the end of 24 and hopefully early.
Five.
[laughter] I understand I was just trying to think I was yeah, I I understand with a preapproval one as I was just always.
I was wondering if they needed to be back in before you could.
Yeah, I have an additional inspection before you could do it either manufacturer ship.
Uhm.
And I want to say you know thanks for the details and I'm 24.
Look at the $50 million.30 would it be prudent for us to pull that out sort of the first half of the year given that you know you'd think it'd be selling.
Where would there be any lingering impact that we should be thinking about next year. Thank you.
Yeah. Thank you I'll take that one so from a 2024 perspective for the Boston impact that we communicate it again. This assumes that we start resume shipping mid to late Q2 to your point much of that impact will be reflected in the first half ourselves of the year.
I think that there will be a natural ramp up right to get back into market. It back up to full full distribution estimate discussed earlier.
Thank you.
Thank you for your question one moment for the next question.
And our next question will be coming from <unk> Chopra of Wells Fargo. Your line is open.
Good morning, and thank you for taking the questions I guess, just Leah woke up looking forward to working with you.
Thinks it.
The color on the 2024 guidance. So I'm just curious how does the preliminary point 24 guidance.
Impact the L. R. Legal you provided and May how confident are you in that five to six per cent 24 to 25, Hello, Hello repeat growth I'll go with them and then I had a follow up please.
So let me start and then I'll, let you on time in and I think it's good to hear from you again as well so forth from L. R. P perspective, we are not officially providing any guidance or update with respect to our LLP, but let me tell you some of the things that I'm excited about in terms of.
What we saw in this quarter that I think bear witness on what we have the potential to do consistent with what we outlined in R. L. R. P.
To your point, if you look at our results in Q2 X Boston what you saw is through the first half both the nurse surgery as well as tissue tag performed that levels are consistent with the growth expectations that we outlined in the ALR pay which to me says, they're the potential to live and to exactly what we.
We already communicated as part of our Investor Day, I think what you also saw was we advanced.
Commitments around the clinical filing for the third has been TMA, we completed our doors or clinical enrollment all of which were critical steps in terms of us being able to once again drive some of the growth that we communicated as part of our Investor day. So I think I'll have that underlying strength in there.
But what will happen over the next couple of months, we do an annual update <unk> pain. So we will have to factor in everything we've talked about the Boston impact to understand what that the broader trajectory impact is across the R. P and will come back to have that conversation, but I still think there's lots of good reasons to believe that the strength is spelled.
There and we have the potential to deliver as as they discussed.
Great. Thank you for the color and then just me one high level of question for me.
What are your assumptions per macro headwinds in the back half of the year, maybe just talk about what getting better and what's getting worse. Thank you.
So let me let me start there.
Sure My prepared remarks that home from a market dynamic procedures perspective.
Let me see dynamic <unk>.
Much across.
The World Europe is.
Doing solids strength and.
Asia and U as market G. I B C put too much coming in as we are expected and see that that'd be expected to continue.
Over the year also when we talk outside U S.
Opportunities deeper penetration and market so.
Independent of what the market goldfish, we have our.
Penetration opportunities to.
Foster and.
The market.
From a supply situation, which over the past year, we've talked about here.
Seen the gradual improvement.
I would consider were relatively back to normal.
World, but I think that's the new normal.
With our suppliers that are not sitting on over capacity are a bit less reliable than before.
<unk> continued to see some discontinuation of products of components will leads to.
Recertification of new components at work too.
Organisation, but at this point in time, we have to process and the resourcing to take up that additional work. So we've seen the over the first half some improvement in our own execution on yields let's see the results of that in the second half.
In terms of lowering.
Orders.
So from that perspective.
The second half received more.
Tailwind stand the headwinds.
Thank you for your question.
One moment, while we prepare for the next question.
And our next question will.
Will be coming from Richard.
<unk> <unk>.
Securities Your line is open.
Hi, Thanks for taking the question. This is Sam on for rich.
The first one on the timeline for the facility how confident are you in that.
Timeline holding the plan is there anything in the process that could.
Cause the restart time and to change for the that'd be earlier or later.
Okay.
Yeah. Thank you. Thank you for this question is as I indicated before it just says a holistic plan.
With all the breath and adapt of observations over the past year.
That's a different work stream the resourcing there.
So in that sense.
It has some contingency and it's for unforeseen things that may happen.
The biggest the elements that.
We are watching closely wouldn't be elements of validation that verification, which doesn't succeed.
The first time and would eat a second try to get there. So we build some of that contingency in.
But the risk the risk is there and as I said before it would try and go with the month of August and September to really.
Those areas.
They have risks and we're trying to pull in.
Sources as well as yeah, that'd work as early as can to give us a tougher to deal with it if that would.
<unk>.
Alright, so build on that.
So if I can just build on that appointment with.
With respect to the timeline, which which I totally agree that I think what was interesting, but you have to understand about the plan. This is a rather large remediation but to yards point at the way we structured the plan and how we plan to execute against S to the extent, we do realize some of the opportunity or <unk>.
<unk> <unk>, where we might have to rework our repossession that that would occur in all likelihood earlier in the timeline versus later so that as we progress through we'll have more information to be able to understand better the exact timing, which is why we've also strategically layered and independent reviews.
The way to help mitigate some of that risk and take advantage of opportunities to pull for if I were a cat or we can to keep the timeline hall.
Okay. So maybe on the third quarter call. We can have a better idea of how solid that timeline is that correct characterization.
Definitely definitely.
And then with regards to the Opex room should we.
One what what do you think you need to see to get confident in wrapping up aspects of normalised level and should we expect that to happen to the first half 24 or is that not going to happen until after manufacturing regimes. Thanks for taking questions.
Questions.
So let me start there and you can.
From an opex perspective, as we move into 20th 94, and we continue to kind of evaluate what what's needed to make sure. We get the the plant restarted we have commercial distribution you start regaining our share we will have to continue to to temper some of our opex spending.
Again, we will always prioritize the strategic investments that are fuelling, our long term growth consistent with what we did this year. So that behavior will continue to progress in 2024, and then I and you know as we start shipping and start realizing kind of the return.
To market that we anticipate that's when I would also expect us <unk> normal returned to to our Opex levels.
Thank you for your question one moment, while we prepare for the next question.
And the next question.
Will be coming from Ryan Zimmerman.
B T I G. Your line is open Oh, great.
Thanks for taking my questions couple for me. So we've we've obviously talk open off about the Boston facility, but I I do have one question on tissue technologies and one on C. S. S and so the first one related to tissue technologies is just you know.
We've given the recall given given the the impact to private label I'm curious kind of.
How how are your private label customer seeking alternative sources in this period and.
And what does that present in your guys' view as a risk longer term to recoupment of the private label business.
And and and just the impact on margins for that private label visits and I know there isn't a lot of operating expenses associated with it but it does it is quite profitable on on the EBIT margin lines. So curious to if you could speak on that and then I'll just ask another question, which C. S. S was was very nice this quarter I.
You know in the neural market relative to the comp last year, and so yeah and I'd like your perspective on the narrow market. The health of it how you would characterize it and why you know it was as strong as it was this quarter. Thanks for taking the question.
Let me <unk> Craig's great questions, but wait so on private label. It we're working very closely.
With our partners too.
I understand.
Where we can help them and make sure that they have full transparency.
Timelines.
Private label partners went into timelines that'd be talk.
It's easy to switch to.
Two other.
Technologies are providers and hence.
The big focus on making sure we work with them.
And make sure they get back as soon as we get other.
Other customers back.
And a second your question of the C. S S markets.
With markets, but you guys as you know.
Many of our procedures and CSS are nuts elective procedures and so S.
The distractions gets out of the market, but also distractions in our own operation that has led.
To some back orders are getting out of the world.
<unk> really seeing the full dynamic of the market's translates into our sales. So it's it's those two elements.
Conjoined too that are driving a good CSS performance over the.
Second quarter.
Okay.
I'll sneak one more than just for where I don't want to leave around just you know you where you called out the leverage ratio [noise].
You called the laboratory sure I think a 2.6 times when I'm mistaken what you know given given your new in the feet, maybe just helping most investors understand what's your comfort with leverage I mean, you know obviously in Patrick took on a lot of that during the common deal years ago, and then work to pay that down but.
What's the comfort what's the right rein for you in terms of leverage for the confidence.
Yeah. Thank you I appreciate the question and I think you know, we we've had a <unk> apparently disciplined kind of capital allocation methodology and as we think about beverage <unk>.
Discipline in that regard as well right now the range that we tend to operate in is 2.5 to 3.5 times is kind of the range, we wanna be and so with that as a guide we're actually at the low end.
What we would team acceptable and appropriate for this business.
Okay I'll leave it there thanks for taking my question.
My friend.
One more for next question.
And our next question will be coming from drew.
Mary.
Morgan Stanley Your line is open.
Hi, Thanks for taking the questions maybe just earlier to to start maybe a couple of quick ones here, but when we're looking at your twenty-three guidance I I understand that there's a lot going on particularly in the tissue technology business lots of fun, but it can maybe help us with your expectations for.
And those two segments.
Imagine maybe CSS might be closer to your long range plan, which help us frame that I then second just on the instrumentation instruments performance in CSS touch on or a surgery a bit.
The prior question, but Ah just anything drunk driving the strengths there you called out kind of for a favorable order timing just any expectation to the back half there for the business that I have a follow up thanks.
Alright, well. Thank you for a tissue technologies I think consistent with what we saw in Q2.
Where are the underlying performance and that business X, but actually take you through the first half and tissue technologies. The underlying performance that does this you know I put high single digits.
For.
For the second half I would anticipate it being in the same range again X Boston, Alright, and we've already framed out for your kind of what we anticipate the Boston impact B for the four year on C. S. S side I think you had a separate question in terms of for the balance of the year again believe this trend and that does.
<unk> will continue to process much like what John already referenced in answer to the previous question and so yeah I would expect that that performance to hold during the balance of the year and then I think your final question was with respect to.
Alright instrument isn't it.
Instrument strong double double digit growth in the quarter I think in the past we've seen some lumpiness in that business I think you'll see that a moderate back too it's kind of typical longterm growth rates, we will continue to experience it necessarily at the same degree that we saw it in the square.
At at a couple of things they're true.
Specific.
What we do see is one the strength of the specialty instruments in that portfolio and in seconds.
For more than a year, we have strength of the commercial.
Mm dynamic, they're focusing on signing up new accounts and.
I think part of that we're seeing the fruits of that investment last year.
In broadening our commercial.
Print a commercial dynamic.
[noise] got it. Thanks I appreciate the color there and I I know you touched on M&A a bit earlier and again I appreciate the dynamics happening in tissue technology, but with the P. F. S wrote the proposal that came out a few weeks ago yawn.
Is there any kind of change in your view strategically longer term about entering more of the non acute setting and tissue tack more enforce are are you more open to doing M&A. In this in this category have you just kind of seemed like what you need to see to be more aggressive and getting into getting into the nonacute space, but extra <unk>.
The question.
Yeah, it's been communicated during the day.
On the kids face is a strategic place to be.
The question is when when is the right time and giving some.
Of the remaining uncertainties in that space.
I consider that.
Some decisions had been pushed out and so we will continue to watch.
That's area closely and both internal and external what would be the right time to.
<unk> moved here.
Thank you.
This does conclude our conference for today. Thank you all for your question you may I'll disconnect and everyone have a great day.
[music].
Okay.
[music].